ATG Individualized Dosing Model in URD-PBSCT.

Abroad (travel likely)RecruitingPHASE2

Conditions

Cytomegalovirus Infections · Infection Reactivation · Stem Cell Transplant Complications

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Hematology, First Medical Center of Chinese PLA General Hospital, Beijing, China
Contact: Study coordinator (jiang Cao) · 010-66937166

Study leads

diahong Liu, MD
Principal Investigator
The First Medical Center of Chinese PLA General Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Adenovirus · Cytomegalovirus Infections · Epstein-Barr Virus Infections

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Palo Alto, United States

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Adenovirus Infections · Cytomegalovirus Infection

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Los Angeles, United States

CMV-CMI in csCMVi After HSCT

Cytomegalovirus Infections · Hematopoietic Stem Cell Transplantation (HSCT) · Immune Reconstitution

Abroad (travel likely)Recruiting

Suzhou, China

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Cytomegalovirus Infections

Abroad (travel likely)Recruiting

Houston, United States · Brussels, Belgium